Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.5K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.5K
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

1.4K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
1.4K
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.9K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.9K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.1K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of the 2016 revisions to the WHO classification in lower-risk myelodysplastic syndrome.

American journal of hematology·2017
Same author

Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.

Cancer·2017
Same author

Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents.

American journal of hematology·2017
Same author

An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes.

American journal of hematology·2017
Same author

Corrigendum: Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia.

Nature immunology·2017
Same author

Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma.

American journal of hematology·2017

Related Experiment Video

Updated: Oct 19, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.9K

Myelodysplastic Syndromes: A New Decade.

Virginia O Volpe1, Guillermo Garcia-Manero2, Rami S Komrokji1

  • 1Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL.

Clinical Lymphoma, Myeloma & Leukemia
|September 21, 2021
PubMed
Summary

Myelodysplastic syndromes (MDS) are clonal stem cell disorders increasing with age. Risk stratification and molecular testing guide personalized treatment for better outcomes, especially in high-risk patients.

Keywords:
High riskHypomethylating agentsIPSS-RLow riskMDSNovel therapiesSomatic muations

More Related Videos

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.9K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.5K

Related Experiment Videos

Last Updated: Oct 19, 2025

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.9K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

11.9K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.5K

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Biology

Background:

  • Myelodysplastic syndromes (MDS) are heterogeneous clonal hematopoietic stem cell disorders.
  • MDS incidence rises with age, particularly over 70.
  • Risk stratification impacts prognosis, acute myeloid leukemia (AML) transformation, and survival.

Purpose of the Study:

  • To summarize current approaches to risk stratification and treatment in MDS.
  • To highlight the role of molecular genetic testing in personalized therapy.
  • To discuss the evolving treatment landscape and future directions for improving survival in MDS.

Main Methods:

  • Review of epidemiological data (SEER 2020) on MDS incidence.
  • Application of the revised International Prognostic Scoring System (IPSS-R).
  • Integration of molecular genetic testing for personalized treatment strategies.

Main Results:

  • Low-risk MDS often managed with supportive care for cytopenias, primarily anemia with erythroid-stimulating agents.
  • High-risk MDS requires prompt treatment, with hypomethylating agents (HMA) as frontline therapy.
  • Allogeneic stem cell transplant offers a potential cure for eligible high-risk MDS patients.

Conclusions:

  • Personalized therapy for MDS is increasingly guided by molecular genetic testing.
  • Novel targeted agents are expanding treatment options, aiming to improve survival.
  • Focus remains on enhancing outcomes for relapsed/refractory and transplant-ineligible MDS populations.